ANSWER: B

Rationale:

Option B is correct. This patient's presentation is classic peak-dose dyskinesia (PDD): involuntary choreiform movements that emerge approximately 45 minutes after the levodopa dose — when plasma concentrations near their peak — and resolve as the dose wears off. The patient remains functionally mobile during episodes, consistent with being in the "on" state. PDD arises from years of pulsatile, non-physiological dopamine receptor stimulation in the setting of progressive nigrostriatal degeneration, which sensitizes direct pathway medium spiny neurons through deltaFosB accumulation and downstream NMDA/AMPA receptor changes. The movements appear when receptor stimulation is most intense and resolve with falling concentrations.

• Option A: Option A is incorrect; it describes off-period dystonia, which occurs at trough levodopa levels from insufficient dopaminergic stimulation — the opposite temporal pattern, and the patient here has good motor function during movements.
• Option C: Option C is incorrect; it describes diphasic dyskinesia, which occurs at rising and falling intermediate concentrations, not at peak, and tends to involve stereotyped leg movements rather than choreiform trunk and arm movements.
• Option D: Option D is incorrect; cholinergic excess in the off state would produce rigidity and bradykinesia, not choreiform movements at peak dose.
• Option E: Option E is incorrect; dopamine receptor downregulation would reduce, not produce, dyskinesia, and paradoxical motor responses at normal concentrations is not a recognized pathophysiological mechanism for LID.

ANSWER: D

Rationale:

Option D is correct. This patient has diphasic dyskinesia — involuntary movements that appear as plasma levodopa rises at the beginning of a dose response (beginning-of-dose, BOD dyskinesia) and again as levels fall at the end (end-of-dose, EOD dyskinesia), with relative freedom during the peak. This is the opposite temporal profile from peak-dose dyskinesia. The critical management principle is that reducing the individual levodopa dose will worsen diphasic dyskinesia, specifically the BOD component, because it lowers the peak concentration that the dose must traverse on the way up — prolonging the time spent at the intermediate concentrations where dyskinesia is triggered and reducing the effective on-state duration. This is a common clinical error when diphasic dyskinesia is misidentified as peak-dose dyskinesia.

• Option A: Option A is incorrect; a COMT inhibitor reduces trough depths and extends levodopa half-life, which would attenuate the concentration fluctuations that drive both components of diphasic dyskinesia — a rational intervention.
• Option B: Option B is incorrect; continuous intestinal gel infusion is one of the strongest therapeutic strategies for diphasic dyskinesia because it eliminates the dose-by-dose concentration fluctuations entirely, converting a pulsatile profile to a near-continuous one.
• Option C: Option C is incorrect; adding a long-acting dopamine agonist provides continuous receptor stimulation that bridges concentration troughs, reducing the depth of the trough-related dyskinesia trigger — another rational approach.
• Option E: Option E is incorrect; more frequent dosing reduces the interval between doses and shortens the trough period, which tends to reduce the duration of the intermediate-concentration windows that trigger diphasic dyskinesia, not worsen it.

ANSWER: A

Rationale:

Option A is correct. This patient has classic off-period dystonia — specifically, early morning foot dystonia, one of the most recognizable presentations of this phenomenon. The cramping and equinovarus posturing occur at 5 AM, hours after his last evening levodopa dose and two hours before his first morning dose, precisely when plasma levodopa levels are at their overnight nadir and dopaminergic stimulation is at its lowest. Off-period dystonia is pathophysiologically distinct from levodopa-induced dyskinesia: it results from insufficient dopamine rather than excessive pulsatile stimulation, and reflects the consequence of the untreated or under-treated off state in the basal ganglia motor circuit. The resolution with movement and activity is consistent with mild improvement as endogenous dopamine is mobilized. Management targets extending dopaminergic coverage through the overnight period, typically with CR carbidopa/levodopa at bedtime.

• Option B: Option B is incorrect; peak dopamine stimulation producing dyskinesia would require recent levodopa ingestion, and the movements described are sustained dystonic contractions, not choreiform, and occur at a time when levodopa levels are minimal.
• Option C: Option C is incorrect; diphasic dyskinesia requires transition between intermediate concentrations associated with a dose cycle, not overnight periods with no recent levodopa intake.
• Option D: Option D is incorrect; cholinergic excess can contribute to rigidity and tremor in PD but does not explain the overnight timing or the foot-specific dystonic pattern described.
• Option E: Option E is incorrect; D2 autoreceptor activity reducing nigrostriatal output is not a recognized mechanism for off-period dystonia, and this mechanism would be expected to produce bradykinesia rather than painful focal dystonic posturing.

ANSWER: C

Rationale:

Option C is correct. The clinically essential distinction between peak-dose dyskinesia (PDD) and diphasic dyskinesia is their timing relative to the plasma levodopa concentration curve during a single dose cycle. PDD occurs at or near peak concentrations — when the patient is functionally "on" and motor function is best — and resolves as concentrations decline. Diphasic dyskinesia occurs at intermediate concentrations during the rising phase (beginning-of-dose) and again during the falling phase (end-of-dose), with a window of relative dyskinesia freedom during the peak. This timing distinction determines management: PDD responds to strategies that reduce peak concentration amplitude, while diphasic dyskinesia worsens with dose reduction and requires strategies that minimize concentration fluctuations, ideally achieving continuous delivery.

• Option A: Option A is incorrect; sustained painful contractions describe off-period dystonia, not peak-dose dyskinesia. PDD consists of choreiform movements that are often well tolerated, but the distinguishing feature is not movement quality alone — it is timing relative to the dose cycle.
• Option B: Option B is incorrect; dopamine receptor downregulation and D1 upregulation do not mechanistically distinguish PDD from diphasic dyskinesia in the clinical framework used to guide management decisions.
• Option D: Option D is incorrect; PDD more typically involves the trunk and upper extremities with choreiform movements, while diphasic dyskinesia more often involves stereotyped, rhythmic lower extremity movements — the description in this option reverses the typical phenomenology.
• Option E: Option E is incorrect; while it is true that PDD responds to dose reduction strategies and diphasic dyskinesia worsens with them, stating that both improve with dopamine agonist addition oversimplifies and conflates the mechanisms; the key distinction is the dose-cycle timing, not the differential response to agonists.

ANSWER: E

Rationale:

Option E is correct. In the intact nigrostriatal system, the high density of dopaminergic terminals and their vesicular storage capacity act as a pharmacokinetic buffer: they absorb peaks in levodopa-derived dopamine when synthesis is high and release stored dopamine during troughs, maintaining relatively stable synaptic concentrations. As nigrostriatal degeneration progresses and terminal density falls, this buffering capacity is progressively lost. Each oral levodopa dose then produces an extreme oscillation in synaptic dopamine — rapid saturation of postsynaptic receptors during absorption followed by near-complete depletion as the dose wears off. It is this amplitude of receptor occupancy swing, not the absolute dose, that drives the molecular sensitization underlying dyskinesia. Patients with greater terminal loss experience greater swings per dose, explaining why disease severity and younger age at onset (associated with more aggressive nigrostriatal loss relative to reserve) predict dyskinesia risk more reliably than levodopa dose.

• Option A: Option A is incorrect; D1 receptor upregulation in response to denervation contributes to postsynaptic sensitization but does not make receptors constitutively active in a manner that produces dyskinesia without levodopa — the pulsatile stimulation from levodopa dosing remains necessary to drive sensitization.
• Option B: Option B is incorrect; while serotonergic terminal sprouting and non-vesicular dopamine release from dorsal raphe neurons does contribute to dyskinesia in advanced disease, this is a secondary mechanism, not the primary presynaptic explanation for why terminal loss increases dyskinesia risk.
• Option C: Option C is incorrect; the remaining dopaminergic neurons do increase their firing rate compensatorily in early PD, but this autoreceptor-related mechanism does not explain the dose-by-dose buffering failure that underlies dyskinesia sensitization.
• Option D: Option D is incorrect; NMDA receptor upregulation in the striatum is a postsynaptic change that contributes to dyskinesia expression but is not the presynaptic buffering mechanism described in the question stem.

ANSWER: B

Rationale:

Option B is correct. DeltaFosB is the transcription factor most consistently linked to the molecular sensitization that underlies levodopa-induced dyskinesia in both rodent and primate models. Repeated pulsatile D1 receptor stimulation activates adenylyl cyclase, elevates cyclic AMP, activates protein kinase A (PKA), and phosphorylates DARPP-32 and the transcription factor complex that drives FosB gene expression. Unlike full-length FosB, which is rapidly degraded, deltaFosB is a truncated isoform that accumulates progressively with each exposure due to its resistance to proteasomal degradation. Its accumulation in direct pathway medium spiny neurons drives transcriptional changes including upregulation of AMPA receptor GluA1 subunits and NMDA receptor NR2B subunits, increasing the sensitivity of those neurons to both dopaminergic and glutamatergic inputs. This molecular sensitization is a consistent correlate of dyskinesia severity across animal models of PD.

• Option A: Option A is incorrect; CREB phosphorylation by PKA does occur in response to D1 stimulation and is part of the signaling cascade, but CREB is not the primary molecular marker of LID sensitization — it mediates acute gene transcription responses rather than the progressive accumulation that characterizes dyskinesia development.
• Option C: Option C is incorrect; NF-κB activation in the striatum is associated with neuroinflammation rather than the dopaminergic sensitization cascade that specifically underlies LID, and is not the transcription factor identified as a molecular marker of dyskinesia in the standard pharmacological literature.
• Option D: Option D is incorrect; ATF3 upregulation in the indirect pathway is not the mechanism described for LID sensitization — the sensitization in LID is centered on the direct pathway D1-expressing MSNs, not indirect pathway neurons.
• Option E: Option E is incorrect; full-length FosB is indeed rapidly degraded, allowing deltaFosB to accumulate, but deltaFosB does not compete with full-length FosB in a manner that determines a sensitization-versus-tolerance outcome — this framing misrepresents the actual molecular relationship described in the LID literature.

ANSWER: D

Rationale:

Option D is correct. DARPP-32, dopamine and cyclic AMP-regulated phosphoprotein of 32 kDa, is the key convergence phosphoprotein in the D1 receptor signaling cascade in striatal medium spiny neurons. Pulsatile D1 receptor stimulation activates Gs-coupled adenylyl cyclase, elevates cyclic AMP, and activates protein kinase A (PKA). PKA phosphorylates DARPP-32 at threonine-34, converting it into a potent inhibitor of protein phosphatase 1 (PP1). This amplifies and sustains PKA-dependent signaling, including phosphorylation of downstream targets. The resulting cascade drives expression of FosB gene products, with progressive accumulation of the stable deltaFosB isoform that mediates the transcriptional changes underlying LID sensitization. DARPP-32 is explicitly identified in the Park-03 module as part of the molecular pathway from D1/cAMP through PKA to deltaFosB accumulation.

• Option A: Option A is incorrect; alpha-synuclein phosphorylation at serine-129 is associated with Lewy body formation and PD pathology, not with the D1 receptor signaling cascade that drives LID sensitization in the direct pathway.
• Option B: Option B is incorrect; synapsin I phosphorylation regulates presynaptic vesicle dynamics at dopaminergic terminals, not postsynaptic signaling in medium spiny neurons — it is not part of the LID sensitization cascade.
• Option C: Option C is incorrect; GluA1 phosphorylation at serine-845 by PKA does occur downstream of D1 stimulation and does increase AMPA receptor surface expression, contributing to sensitization, but GluA1 is a glutamate receptor subunit whose expression is altered as a consequence of deltaFosB accumulation — it is not the primary convergence phosphoprotein in the cascade as described in the module.
• Option E: Option E is incorrect; D1 receptors are Gs-coupled, not Gq-coupled, and signal through adenylyl cyclase and cyclic AMP rather than through phospholipase C-beta, inositol trisphosphate, or protein kinase C.

ANSWER: A

Rationale:

Option A is correct. The glutamatergic permissive mechanism is the pharmacological rationale for NMDA receptor antagonism as an antidyskinetic strategy. Repeated pulsatile D1 receptor stimulation sensitizes direct pathway medium spiny neurons (MSNs) through the deltaFosB-mediated transcriptional changes described in Section 2 of the Park-03 module. However, these sensitized MSNs require concurrent glutamatergic input from the corticostriatal pathway — acting through AMPA and NMDA receptors — to generate the full dyskinetic motor output. The glutamatergic drive acts permissively: it enables the expression of dyskinesia in already-sensitized neurons but is not the primary sensitizing signal. By blocking NMDA receptors with an uncompetitive antagonist such as amantadine, this permissive glutamatergic gate is partially closed, reducing dyskinesia expression without substantially altering the dopaminergic stimulation that produces the desired on-state motor benefit.

• Option B: Option B is incorrect; amantadine does not reduce dopamine synthesis by blocking calcium-dependent tyrosine hydroxylase activation — its antidyskinetic mechanism is postsynaptic NMDA receptor antagonism, not presynaptic dopamine synthesis inhibition.
• Option C: Option C is incorrect; amantadine acts at postsynaptic NMDA receptors on striatal medium spiny neurons, not on presynaptic dopaminergic terminals, and does not reduce vesicular dopamine release.
• Option D: Option D is incorrect; the relevant target in LID management is the direct pathway D1-expressing MSNs, not indirect pathway neurons. Indirect pathway inhibition would reduce GPe inhibitory output, disinhibiting the subthalamic nucleus, which would worsen rather than improve dyskinesia by increasing STN excitatory drive.
• Option E: Option E is incorrect; the mechanism described — amantadine blocking subthalamic nucleus glutamate effects on striatal GABAergic interneurons to reduce inhibitory tone — is a fabricated pathway that does not correspond to the actual mechanism of amantadine's antidyskinetic action as described in the module.

ANSWER: C

Rationale:

Option C is correct. Amantadine is an uncompetitive NMDA receptor antagonist — it enters the NMDA receptor ion channel and blocks it in a use-dependent fashion, meaning it requires the channel to be open (activated by glutamate and glycine co-agonism) to gain access to its binding site within the channel pore. This use-dependence is pharmacologically important: at baseline, when NMDA channels are not excessively activated, amantadine's blocking effect is modest. During periods of excessive corticostriatal glutamatergic drive — which permissively enables dyskinesia expression in the sensitized striatum — the channels are open more frequently and amantadine's blocking effect is proportionally greater. This mechanism reduces dyskinesia expression without substantially impairing normal synaptic transmission or the dopaminergic motor benefit of levodopa. Amantadine also has secondary mechanisms including dopamine release enhancement and reuptake inhibition, but its antidyskinetic action is attributed to NMDA receptor antagonism.

• Option A: Option A is incorrect; amantadine does not act through D2 receptor competitive antagonism — D2 blockade is the mechanism of antipsychotics, which actually worsen parkinsonism.
• Option B: Option B is incorrect; MAO-B inhibition is the mechanism of selegiline, rasagiline, and safinamide — not amantadine. These agents reduce dopamine catabolism and modestly extend on time but are not the primary antidyskinetic therapy.
• Option D: Option D is incorrect; amantadine does not selectively block AMPA receptor GluA1 subunits — this is not a known pharmacological mechanism for any approved antidyskinetic agent and misrepresents amantadine's mechanism of action.
• Option E: Option E is incorrect; while amantadine does have anticholinergic properties that may contribute to tremor reduction, the antidyskinetic mechanism is not muscarinic M1 blockade on striatal interneurons — anticholinergic agents are not used to manage dyskinesias and would not be expected to address the glutamatergic permissive drive underlying LID expression.

ANSWER: E

Rationale:

Option E is correct. Amantadine's ADME profile makes it uniquely dependent on renal clearance for elimination. It has an oral bioavailability of approximately 86–90%, is not substantially metabolized by the liver, and is excreted largely unchanged in the urine. In patients with normal renal function, the plasma half-life is approximately 10–18 hours, allowing twice-daily dosing. Because hepatic metabolism contributes minimally to its elimination, renal function is the primary — essentially exclusive — determinant of clearance. Renal impairment directly prolongs the half-life in proportion to the degree of function loss, increasing plasma concentrations and the risk of amantadine's concentration-dependent adverse effects, particularly neuropsychiatric toxicity including confusion and hallucinations. The Park-03 module specifies dose reduction to 100 mg once daily for creatinine clearance 30–50 mL/min; for CrCl 15–29 mL/min, every-other-day dosing or avoidance is required. This patient's CrCl of 38 mL/min falls in the range requiring dose reduction.

• Option A: Option A is incorrect; amantadine is not extensively metabolized by CYP3A4. Hepatic metabolism is a minor contributor to its elimination, and renal impairment does not act through indirect effects on hepatic blood flow.
• Option B: Option B is incorrect; amantadine is not primarily eliminated by biliary excretion. This mechanism applies to some other drugs (e.g., some macrolides) but not to amantadine, whose dominant route of elimination is renal.
• Option C: Option C is incorrect; amantadine is not highly protein-bound. High protein binding and displacement by uremic solutes is the mechanism relevant for drugs like phenytoin or warfarin, not amantadine.
• Option D: Option D is incorrect; while renal tubular secretion does contribute to amantadine's renal elimination alongside glomerular filtration, the clinically important point is the overall dependence on renal excretion of unchanged drug, not a selective impairment of the tubular secretory mechanism alone.

ANSWER: B

Rationale:

Option B is correct. The evidence base for amantadine as an antidyskinetic agent, as summarized in the Park-03 module, is anchored by multiple controlled trials and a Cochrane review demonstrating that immediate-release amantadine at standard doses (100 mg two to three times daily) reduces peak-dose dyskinesia by approximately 45–60% without a commensurate worsening of motor function in most patients. This dissociation — substantial dyskinesia reduction without proportionate motor deterioration — is the key clinical feature that distinguishes amantadine from strategies that reduce dyskinesia by simply reducing dopaminergic stimulation, which inevitably worsen motor control. Amantadine is the only oral agent with robust Level A evidence for LID reduction and is appropriately considered first-line pharmacological treatment for functionally limiting dyskinesia.

• Option A: Option A is incorrect; the magnitude of effect reported is approximately 45–60% reduction, not 20–25%, and the clinical trial data do not support a proportionate motor worsening — the ability to reduce dyskinesia without worsening motor control is precisely what gives amantadine its therapeutic advantage.
• Option C: Option C is incorrect; amantadine has not been compared head-to-head with GPi DBS in randomized trials demonstrating equivalent efficacy — GPi DBS is reserved for patients with refractory dyskinesias not adequately controlled with optimized oral management including amantadine.
• Option D: Option D is incorrect; while some loss of antidyskinetic effect has been reported with longer-term use in some patients, the module states that the effect is maintained in most patients for at least one year — complete waning within 6–8 weeks in the majority is not consistent with the evidence.
• Option E: Option E is incorrect; amantadine's antidyskinetic efficacy is not restricted to early levodopa use — it is used precisely in patients who have developed established dyskinesias with long-term levodopa therapy, and its mechanism targets the glutamatergic permissive drive rather than preventing initial sensitization.

ANSWER: D

Rationale:

Option D is correct. Livedo reticularis is a well-recognized, common, and distinctive cutaneous adverse effect of amantadine, occurring in up to 50% of patients on long-term therapy. It presents as a mottled, reddish-purple, net-like or lace-like discoloration of the skin, most often affecting the lower extremities. The mechanism relates to altered local vasomotor tone causing venous pooling in the superficial dermal plexus, not to vasculitis, immune complex deposition, or neuropathy. Despite its striking appearance, livedo reticularis from amantadine is benign and does not require drug discontinuation — it can be managed by reassuring the patient and monitoring. In this patient whose dyskinesias are well controlled on amantadine, continuing the medication with explanation is the appropriate response.

• Option A: Option A is incorrect; drug-induced vasculitis from amantadine is not the mechanism of livedo reticularis and is not described as a common adverse effect. The clinical presentation described — mottled discoloration without pain, swelling, or systemic symptoms — is classic livedo reticularis, not vasculitis, which would typically be accompanied by palpable purpura, tenderness, or systemic features.
• Option B: Option B is incorrect; livedo reticularis does not represent or progress to peripheral neuropathy — it is a vasomotor phenomenon, not a neurotoxic one. Amantadine does not cause a small-fiber neuropathy.
• Option C: Option C is incorrect; the presentation is not consistent with contact dermatitis, which would be localized to areas of contact with the capsule material rather than a generalized lower extremity pattern, and type IV hypersensitivity would produce pruritic eczematous changes rather than the net-like vascular pattern of livedo.
• Option E: Option E is incorrect; acrocyanosis involves diffuse blue discoloration of the extremities from sustained vasoconstriction, not a mottled net-like pattern, and is not a recognized adverse effect of amantadine. Amantadine does not act through alpha-adrenergic agonism.

ANSWER: A

Rationale:

Option A is correct. Abrupt discontinuation of amantadine, particularly at high doses, has been associated with a neuroleptic malignant syndrome (NMS)-like state characterized by hyperthermia, severe rigidity, autonomic instability, and altered consciousness. This presentation is analogous to the NMS-like syndrome that can occur with abrupt levodopa withdrawal: amantadine contributes to central dopaminergic tone through its dopamine release-enhancing and reuptake-inhibiting properties, in addition to its NMDA antagonism. Sudden removal of these dopaminergic contributions causes an abrupt reduction in central dopaminergic activity, precipitating a state indistinguishable from NMS. This is an important perioperative prescribing hazard: amantadine must not be abruptly discontinued in patients on chronic high-dose therapy, and the surgical team's error here — stopping amantadine without a taper on the morning of surgery — directly caused this life-threatening complication. The module explicitly notes this risk and the requirement to avoid abrupt discontinuation.

• Option B: Option B is incorrect; serotonin toxicity from levodopa-serotonin interaction is not the mechanism here, and the presentation of amantadine withdrawal does not involve the serotonergic excess features (clonus, hyperreflexia, diaphoresis with normal tone initially) that characterize serotonin syndrome — it reflects dopaminergic withdrawal.
• Option C: Option C is incorrect; while amantadine does have NMDA receptor antagonism, there is no established mechanism by which its withdrawal causes glutamate excitotoxicity severe enough to produce the acute syndrome described within 48 hours, and this is not the recognized clinical mechanism of amantadine withdrawal toxicity.
• Option D: Option D is incorrect; general anesthetic agents do not competitively displace amantadine from NMDA receptors and produce rebound glutamatergic hyperactivation in this manner — this is a fabricated mechanism that does not correspond to known pharmacology.
• Option E: Option E is incorrect; amantadine is not a significant inhibitor of CYP enzymes responsible for carbidopa/levodopa metabolism, and carbidopa/levodopa does not undergo substantial CYP-mediated hepatic metabolism — levodopa is metabolized by aromatic amino acid decarboxylase and COMT, not CYP enzymes.

ANSWER: C

Rationale:

Option C is correct. Gocovri (amantadine extended-release 274 mg) is taken at bedtime and uses a specific release technology designed to produce low plasma concentrations during the sleep period — when the neuropsychiatric adverse effects of amantadine are most problematic — and rising concentrations through the early morning and waking hours, when levodopa-related motor activity and dyskinesia are most prevalent. This pharmacokinetic profile allows delivery of higher total amantadine doses than are typically tolerated with immediate-release formulations because the overnight low-concentration window reduces the likelihood of insomnia and nocturnal confusional episodes. The approved dose of 274 mg nightly produces amantadine exposures exceeding those achievable with standard IR dosing. The pivotal phase 3 trials (EASE LID study and a second confirmatory trial) demonstrated reduction in both peak-dose dyskinesia and off-time — the off-time reduction was not consistently observed with IR amantadine, possibly because the higher exposure levels achieved with the ER formulation provide additional motor benefit.

• Option A: Option A is incorrect; Gocovri does not use enteric-coated microspheres with colonic delivery, and the formulation is specifically a once-nightly bedtime dose, not a morning dose producing lower peaks with equivalent efficacy at the same dose.
• Option B: Option B is incorrect; Gocovri is taken at bedtime, not in the morning — this option reverses the pharmacokinetic profile entirely. High concentrations during waking hours are the goal, achieved by the rising concentration curve through the morning that results from bedtime dosing.
• Option D: Option D is incorrect; Gocovri does not use an osmotic pump (that description fits OROS-type formulations) and does not maintain a flat 24-hour concentration profile — its pharmacokinetic rationale is specifically a pulsatile profile timed to waking hours, not a flat continuous release.
• Option E: Option E is incorrect; amantadine extended-release is an oral capsule formulation, not an intranasal delivery system, and is not a rescue therapy — it is a once-nightly scheduled oral dose.

ANSWER: E

Rationale:

Option E is correct. Levodopa-carbidopa intestinal gel (LCIG, marketed as Duopa in the United States and Duodopa in Europe) is a continuous suspension of levodopa and carbidopa delivered directly into the proximal jejunum via a percutaneous endoscopic gastrostomy with a jejunal extension tube (PEG-J). The pharmacokinetic rationale is that oral levodopa absorption is highly dependent on gastric emptying rate, which is erratic and unpredictable in PD patients (who have impaired gastrointestinal motility as part of the autonomic dysfunction of the disease). By bypassing the stomach and delivering directly to the proximal small intestine — the primary site of levodopa absorption — LCIG provides a continuous, predictable levodopa input that dramatically reduces the peak-to-trough plasma concentration fluctuations responsible for both wearing-off and dyskinesia. The pivotal double-blind, double-dummy randomized controlled trial demonstrated that 12 weeks of LCIG reduced mean daily off-time by approximately 4 hours compared with optimized oral immediate-release carbidopa/levodopa, with parallel reductions in dyskinesia.

• Option A: Option A is incorrect; LCIG is not a subcutaneous intravenous catheter and does not achieve near-100% bioavailability by bypassing hepatic first-pass metabolism — it still undergoes intestinal absorption and portal circulation transit. The bioavailability advantage comes from bypassing gastric emptying variability, not hepatic metabolism.
• Option B: Option B is incorrect; LCIG does not use a pH-sensitive gel matrix that adjusts dose based on gastric acid — it is a manually programmed infusion pump that delivers a set continuous and bolus dose determined by the clinician based on the patient's individualized levodopa requirements.
• Option C: Option C is incorrect; LCIG is not a transdermal patch. Rotigotine is delivered transdermally, but LCIG is a jejunal infusion via a surgically placed tube.
• Option D: Option D is incorrect; LCIG contains levodopa itself, not a prodrug converted to dopamine in the jejunal mucosa. Levodopa still requires peripheral decarboxylation to dopamine (inhibited by carbidopa) and CNS conversion — it does not produce a flat plasma dopamine profile through mucosal conversion.

ANSWER: B

Rationale:

Option B is correct. Peripheral neuropathy is a recognized complication of long-term LCIG therapy and has been identified as a distinct clinical entity associated with the high daily carbidopa doses that LCIG delivers. Carbidopa inhibits aromatic amino acid decarboxylase (AADC), the same enzyme responsible for peripheral conversion of levodopa to dopamine, but it also interferes with pyridoxine (vitamin B6) metabolism — carbidopa forms a hydrazone complex with pyridoxal phosphate, depleting the active form of B6. Vitamin B6 is an essential cofactor for multiple metabolic pathways including homocysteine remethylation, and B6 deficiency causes an axonal sensorimotor polyneuropathy. Additionally, LCIG-related neuropathy has been associated with elevated plasma homocysteine and methylmalonic acid levels, implicating vitamin B12 deficiency as a co-contributing factor. The Park-03 module explicitly identifies this neuropathy as a distinct recognized clinical entity in the context of LCIG complications.

• Option A: Option A is incorrect; PEG site infections producing septic embolic ischemic neuropathy is not a recognized LCIG complication — PEG site infections do occur as a procedural complication, but they cause local wound complications, not a systemic embolic neuropathy.
• Option C: Option C is incorrect; tube displacement causing thiamine deficiency neuropathy is not the recognized neuropathy entity associated with LCIG — while tube displacement is a recognized mechanical complication, the specific nutritional neuropathy linked to LCIG is related to carbidopa-mediated B6 interference, not thiamine deficiency.
• Option D: Option D is incorrect; direct neurotoxicity of levodopa gel on the myenteric plexus causing retrograde axonal degeneration is a fabricated mechanism that does not correspond to any recognized LCIG complication.
• Option E: Option E is incorrect; inflammatory demyelinating polyneuropathy triggered by a foreign-body response to the PEG-J tube is not a recognized complication of LCIG — the neuropathy entity associated with LCIG is an axonal, nutritional neuropathy, not an immune-mediated demyelinating process.

ANSWER: D

Rationale:

Option D is correct. Significant levodopa responsiveness is one of the core selection criteria for DBS candidacy, and the standard threshold used in clinical practice is at least 30–33% improvement in the UPDRS (Unified Parkinson's Disease Rating Scale) Part III motor score during a standardized levodopa challenge. The rationale is mechanistic: DBS modulates the output of basal ganglia nuclei (STN or GPi) to reduce excessive inhibitory drive to the thalamus, thereby improving the same motor symptoms that levodopa improves by restoring dopaminergic signaling through the same circuits. Symptoms that do not respond to levodopa — postural instability, freezing of gait, dysarthria, autonomic dysfunction — will not respond to DBS. A patient who fails to demonstrate adequate levodopa responsiveness is therefore unlikely to benefit from DBS, and proceeding would expose them to surgical risk without meaningful motor benefit.

• Option A: Option A is incorrect; there is no absolute upper age cutoff of 60 years for DBS. Age is considered in the overall risk-benefit assessment, but the landmark trials enrolled patients in their 60s, and chronological age alone is not the determining criterion — overall functional status, cognitive reserve, and comorbidities are more important considerations.
• Option B: Option B is incorrect; disease duration of 10 years does not indicate that the window for DBS has closed. Duration is not a contraindication, and patients with longer disease duration who still have significant levodopa-responsive motor function and refractory motor complications can be appropriate candidates.
• Option C: Option C is incorrect; the presence of wearing-off and peak-dose dyskinesias are actually the primary indications for DBS, not contraindications. DBS is specifically indicated for patients with motor complications refractory to optimized pharmacotherapy, and both STN and GPi DBS improve these complications.
• Option E: Option E is incorrect; bilateral rest tremor is actually one of the symptoms that responds particularly well to both STN and GPi DBS. Tremor is not a predictor of poor DBS response — the tremor circuit does involve the STN and thalamic nuclei targeted by DBS, and tremor-predominant patients often have excellent outcomes with surgical neuromodulation.

ANSWER: A

Rationale:

Option A is correct. The clinical trade-offs between STN and GPi DBS are well characterized, and this patient's profile — mild pre-existing depression, mildly reduced cognitive processing speed, and severe functionally limiting dyskinesias — favors GPi as the target. GPi DBS carries a lower risk of the mood and neuropsychiatric adverse effects that are occasionally seen with STN stimulation, including depression and cognitive changes. The VA/NINDS cooperative study found that GPi DBS patients had better scores on the Mattis Dementia Rating Scale and depressive symptom measures compared with STN DBS patients at 24 months. Critically for this patient, GPi DBS also provides direct antidyskinetic benefit that is independent of levodopa dose reduction — GPi DBS patients can maintain or even increase their levodopa doses if motor symptoms require it, while still achieving dyskinesia control. This is pharmacologically important: GPi stimulation directly modulates the output nucleus where dyskinesias are expressed, reducing involuntary movements without requiring the levodopa dose reduction through which STN DBS achieves its antidyskinetic effect.

• Option B: Option B is incorrect; STN DBS does not produce superior overall motor UPDRS outcomes in all patient subgroups — the VA/NINDS cooperative study found no significant difference in overall motor outcomes between the two targets at 24 months. Superior efficacy of STN over GPi is not an established finding that would justify accepting additional neuropsychiatric risk in a vulnerable patient.
• Option C: Option C is incorrect; GPi DBS does not increase levodopa requirements after implantation — it provides direct antidyskinetic benefit that allows levodopa doses to be maintained or increased if desired for motor benefit, but this is not because GPi stimulation requires higher levodopa doses; rather, it permits them without worsening dyskinesia.
• Option D: Option D is incorrect; STN DBS does not directly suppress direct pathway MSNs. STN is an excitatory nucleus that drives the indirect pathway output, and STN DBS achieves its antidyskinetic effect indirectly — primarily through the secondary levodopa dose reduction it allows, rather than direct dyskinesia suppression at the level of the striatum.
• Option E: Option E is incorrect; the VA/NINDS cooperative study did find equivalent overall motor outcomes but did note important differences in cognitive and mood outcomes favoring GPi, which is precisely why the choice between targets is clinically significant for patients with pre-existing neuropsychiatric vulnerabilities.

ANSWER: C

Rationale:

Option C is correct. The first step in wearing-off management, as described in the Park-03 module management algorithm, is to shorten the dose interval — that is, increase the frequency of daily doses — before increasing the individual dose amount. Most wearing-off represents a timing problem: the dose wears off before the next scheduled dose is due because the inter-dose interval is too long, not because each individual dose is subtherapeutic. Increasing dosing from three to four or five times daily, while maintaining the current individual dose or making only modest increases, typically substantially reduces wearing-off duration by ensuring that the next dose arrives before the previous one has fully dissipated. This approach also avoids amplifying peak levodopa concentrations, which could increase the risk of peak-dose dyskinesia. For this patient who has a 45-minute pre-dose wearing-off window on a three-times-daily schedule, moving to a four-times-daily or five-times-daily schedule is the appropriate first adjustment.

• Option A: Option A is incorrect; doubling the individual dose while maintaining the same frequency addresses peak concentration rather than trough timing — if wearing-off begins 45 minutes before the scheduled dose, the problem is interval length, and a higher dose at the same frequency will not correct the pre-dose trough. It will, however, increase peak concentrations and dyskinesia risk.
• Option B: Option B is incorrect; adding a dopamine agonist may be appropriate later in the management algorithm if dose interval adjustment is insufficient, but it is not the first step and is not indicated before attempting to optimize the levodopa schedule itself.
• Option D: Option D is incorrect; extended-release formulations are an option for some patients, but the evidence for ER reducing wearing-off versus optimized IR dosing is modest, and the module explicitly states that interval shortening is the first step — not immediate switch to ER.
• Option E: Option E is incorrect; COMT inhibitor addition (entacapone or opicapone) is a valid second-line strategy if interval adjustment is insufficient, but the module's management algorithm specifies dose interval shortening as the first intervention, with COMT inhibition as the next step when interval adjustment alone is inadequate.

ANSWER: E

Rationale:

Option E is correct. Catechol-O-methyltransferase (COMT) is a ubiquitous enzyme that methylates catechol compounds, including levodopa, converting it to 3-O-methyldopa (3-OMD) in the peripheral circulation. This peripheral O-methylation is a major route of levodopa catabolism that competes with its decarboxylation to dopamine (inhibited by carbidopa). 3-OMD does not cross the blood-brain barrier effectively, so the fraction of each levodopa dose converted to 3-OMD represents a pharmacokinetic loss that shortens the plasma levodopa concentration curve. By blocking peripheral COMT, entacapone reduces this O-methylation pathway, slowing levodopa clearance and extending its plasma half-life. The result is a broader, longer plasma levodopa concentration curve from each dose: peak concentration is modestly reduced and the duration of the therapeutic concentration window is extended, which reduces wearing-off by prolonging the time spent above the motor threshold. Entacapone is a peripherally acting COMT inhibitor and does not substantially cross the blood-brain barrier.

• Option A: Option A is incorrect; entacapone is a peripherally restricted COMT inhibitor and does not cross the blood-brain barrier to inhibit central COMT in the striatum. Tolcapone, another COMT inhibitor, has some CNS penetrance, but even tolcapone's primary clinical benefit is through peripheral COMT inhibition. The central dopamine metabolite of COMT is 3-methoxytyramine, but this is not the mechanism of entacapone's anti-wearing-off benefit.
• Option B: Option B is incorrect; entacapone inhibits COMT, not aromatic amino acid decarboxylase (AADC). AADC inhibition is the mechanism of carbidopa, which is already present in the regimen. Confusing COMT inhibition with AADC inhibition misidentifies the enzyme target.
• Option C: Option C is incorrect; entacapone acts in the peripheral circulation, not specifically in the gastrointestinal mucosa. While COMT is present in gastrointestinal tissue, entacapone's primary anti-wearing-off mechanism is systemic peripheral COMT inhibition reducing plasma levodopa clearance — not pre-absorptive mucosa-specific inhibition.
• Option D: Option D is incorrect; entacapone inhibits COMT, not monoamine oxidase type A. MAO-A inhibition would be a dangerous mechanism given the tyramine interaction risk (hypertensive crisis). This option confuses two entirely different enzyme systems.

ANSWER: B

Rationale:

Option B is correct. Rasagiline is a selective, irreversible inhibitor of monoamine oxidase type B (MAO-B). In the CNS, MAO-B is the primary enzyme responsible for the oxidative deamination of dopamine to dihydroxyphenylacetic acid (DOPAC) in striatal neurons and glial cells. By inhibiting central MAO-B, rasagiline reduces the rate at which dopamine derived from levodopa is catabolized within the striatum after synthesis and release. This extends the effective duration of each levodopa dose by slowing dopamine turnover — the same amount of levodopa-derived dopamine remains active at postsynaptic receptors for longer because it is metabolized more slowly. Critically, this mechanism is pharmacodynamic (central dopamine catabolism) and is distinct from the pharmacokinetic mechanism of entacapone (peripheral COMT inhibition extending plasma levodopa half-life). The two agents work on different steps of the dopamine pathway and their effects are complementary rather than redundant. Rasagiline does not substantially alter plasma levodopa pharmacokinetics.

• Option A: Option A is incorrect; rasagiline does not inhibit COMT. COMT inhibition is the specific mechanism of entacapone, opicapone, and tolcapone. Rasagiline has no significant COMT-inhibitory activity and adding it to entacapone provides a complementary, not additive-pharmacokinetic, benefit.
• Option C: Option C is incorrect; rasagiline inhibits MAO-B, not aromatic amino acid decarboxylase (AADC). AADC is the enzyme that converts levodopa to dopamine — inhibiting it centrally would reduce dopamine synthesis, which is the opposite of the desired effect. Carbidopa inhibits peripheral AADC; rasagiline has no AADC-inhibitory activity.
• Option D: Option D is incorrect; dopamine transporter inhibition is the mechanism of drugs such as cocaine and some stimulants — rasagiline does not inhibit the dopamine transporter. Amantadine does have modest DAT-inhibiting properties, but this is not the mechanism of rasagiline.
• Option E: Option E is incorrect; rasagiline's clinically meaningful MAO-B inhibition occurs centrally in the striatum, not peripherally. Levodopa is not a substrate for peripheral MAO-B in the manner described, and peripheral MAO-B inhibition is not the mechanism by which rasagiline reduces wearing-off.

ANSWER: D

Rationale:

Option D is correct. The continuous dopaminergic stimulation (CDS) hypothesis, as described in the Park-03 module, holds that the pulsatile nature of oral levodopa administration — not the cumulative dose — is the primary driver of motor complication development and persistence. Oral dosing produces large, rapid swings in striatal dopamine receptor occupancy: from near-saturation during peak absorption to near-zero as the dose wears off. Repeated many times daily for years, these oscillations initiate the molecular sensitization cascade — pulsatile D1 receptor activation, DARPP-32 phosphorylation, deltaFosB accumulation, NMDA/AMPA receptor upregulation — that underlies levodopa-induced dyskinesia. The primate experiment described provides direct evidence for this hypothesis: the same total daily dose produces substantially fewer dyskinesias when delivered continuously, because continuous delivery eliminates the receptor occupancy oscillations without reducing total dopaminergic exposure. The CDS hypothesis is the mechanistic foundation for all continuous delivery approaches (LCIG, subcutaneous apomorphine infusion) and provides the rationale for why these therapies reduce both wearing-off and dyskinesias simultaneously.

• Option A: Option A is incorrect; the CDS hypothesis is not about receptor desensitization and re-sensitization requiring rest periods — it is specifically about the harm of pulsatile oscillations in receptor occupancy. Receptor desensitization is actually less of a problem with continuous stimulation, not more.
• Option B: Option B is incorrect; the CDS hypothesis does not propose that continuous delivery increases total dopamine synthesis or raises the dopamine set-point — it proposes that the pattern of stimulation (continuous vs. pulsatile) determines the degree of sensitization, not the amount of synthesis.
• Option C: Option C is incorrect; this option inverts the core claim of the CDS hypothesis. The hypothesis explicitly holds that cumulative dose is not the primary driver — pulsatile oscillations are. Continuous delivery at the same total daily dose still reduces complications, because it is the pattern, not the quantity, that matters.
• Option E: Option E is incorrect; continuous levodopa delivery does not allow nigrostriatal neurons to recover or restore physiological dopaminergic tone — PD involves irreversible neuronal loss and the disease continues to progress regardless of delivery method. The CDS approach manages receptor stimulation pattern; it does not restore neurons.